High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia

详细信息    查看全文

• 作者：Yinjun Lou ; Wenbin Qian ; Haitao Meng ; Wenyuan Mai ; Hongyan Tong ; Yin Tong ; Jian Huang ; Jie Jin ; ^{zjuhematology@163.com}
• 关键词：Acute promyelocytic leukemia ; Arsenic trioxide ; All-trans retinoic acid ; Central nervous system ; Relapse
• 刊名：Leukemia Research
• 出版年：2013
• 出版时间：January, 2013
• 年：2013
• 卷：37
• 期：1
• 页码：37-42
• 全文大小：526 K

文摘

We conducted a retrospective study to evaluate the efficacy of combining arsenic trioxide (ATO) with all-trans-retinoic acid (ATRA) based induction therapy, followed by 3 courses of consolidation chemotherapy and 2-year sequential ATO/ATRA maintenance therapy in acute promyelocytic leukemia (APL). 137 patients were enrolled in the study. The complete remission (CR) rate was 93.4 % . All the 9 (6.6 % ) induction failures were due to early death. With a median follow-up of 35 months, 5 relapses (4 % ) in CR patients were recorded, including 3 isolated CNS relapses. By using the Kaplan-Meier analysis, the 5-year overall survival and relapse-free survival of the low/intermediate risk group and high-risk group was 98.9 % versus 97.4 % and 98.7 % versus 87.9 % , respectively. The results indicated that ATO based first-line protocol is highly effective for treatment of newly diagnosed APL.